Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daylight-PDT for actinic keratosis: Hexvix vs Metvix
2013-001389-40Phase 4Completed
- Sponsor
- Mari Grönroos
- Start
- Jan 2014
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of hexaminolevulinate and methyl aminolevulinate in actinic keratosis (AK) (2 arms), sponsored by Mari Grönroos. Primary endpoint: clinical and histological healing of actinic keratoses. Started Jan 2014; status: completed.
02
Drugs
hexaminolevulinatemethyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2013-001389-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001389-40.